Welcome to our dedicated page for Korro Bio SEC filings (Ticker: KRRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Korro Bio, Inc. filings document the regulatory record of a biopharmaceutical company developing RNA-editing genetic medicines through its OPERA® platform. Its 8-K reports disclose operating and financial results, corporate presentations, clinical and regulatory program updates, capital-structure activity, and material events tied to its RNA-editing pipeline.
The company’s filings also cover proxy governance, executive compensation, equity incentive and inducement arrangements, employment agreements, and material collaboration and license agreements. Program-related disclosures focus on KRRO-121, hyperammonemia in urea cycle disorders and hepatic encephalopathy, GalNAc-conjugated oligonucleotide research, alpha-1 antitrypsin deficiency, risk factors, and the financing and governance framework supporting Korro Bio’s development-stage operations.
Korro Bio, Inc. Chief Operating Officer Todd Chappell reported the sale of 3,168 shares of common stock on June 16, 2026 at a weighted-average price of $10.83 per share. According to the disclosure, this was a mandatory sale solely to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units granted under the company’s 2023 Stock Option and Incentive Plan. After this tax-related sale, Chappell holds a total of 16,964 shares, which includes 10,066 shares underlying an RSU award scheduled to vest on December 15, 2026, subject to his continued service with the company.
Korro Bio, Inc. Chief Scientific Officer Vincent Loic A reported a sale of 3,418 shares of common stock at a weighted-average price of $10.83 per share. According to the disclosure, this was a mandatory sale solely to satisfy tax withholding obligations from vesting of a restricted stock unit granted under the 2023 Stock Option and Incentive Plan.
After this tax-related transaction, he holds 18,297 shares of common stock, including 10,858 shares issuable upon settlement of an RSU that is scheduled to vest on December 15, 2026, subject to continued service with the company.
Korro Bio, Inc. General Counsel Jeffrey Cerio reported an open-market sale of 6,609 shares of common stock at a weighted-average price of $10.83 per share. According to the filing, this was a mandatory sale solely to satisfy tax withholding obligations from vested restricted stock units under the 2023 equity plan.
After this transaction, Cerio holds 35,293 shares directly, including 20,951 shares underlying restricted stock units that are scheduled to vest on December 15, 2026, if his service with the company continues through that date.
Korro Bio, Inc. Senior Vice President of Finance Oliver Dolan reported an open-market sale of 3,383 shares of common stock on June 16, 2026 at a weighted-average price of $10.83 per share. According to the footnotes, this was a mandatory sale solely to cover tax withholding obligations arising from the vesting and settlement of restricted stock units (RSUs) granted under the company’s 2023 Stock Option and Incentive Plan.
After this transaction, Dolan holds 18,099 shares of common stock directly, which includes 10,741 shares issuable upon settlement of an RSU that is scheduled to vest on December 15, 2026, provided he maintains a continuous service relationship through that date.
Korro Bio director Ali Behbahani received a grant of stock options covering 14,677 shares of common stock at an exercise price of $10.59 per share. These options were awarded at no upfront cost and expire on June 9, 2036.
The options vest in full on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, subject to his continued service as a non-employee director. Following this award, Behbahani holds 14,677 stock options directly.
Korro Bio, Inc. director Rachel Meyers received a grant of stock options as part of her compensation. The award covers 14,677 options to purchase Common Stock at an exercise price of $10.59 per share, all held directly after the transaction.
These options vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual meeting of stockholders, provided she continues serving as a non-employee director through that date. The options are scheduled to expire on June 9, 2036, giving a long-dated incentive aligned with the company’s share price performance.